BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
59.33
+0.46 (0.78%)
At close: Jul 24, 2026, 4:00 PM EDT
59.50
+0.17 (0.29%)
After-hours: Jul 24, 2026, 7:34 PM EDT
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
According to 25 analysts polled by S&P Global, BioMarin Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $87.92. The average 1-year stock price forecast is 48.19% higher than the current stock price, while the lowest is $50 (-15.73%) and the highest is $120 (+102.26%).
Price Target: $87.92 (+48.19%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 14 | 14 | 14 | 14 |
| Buy | 4 | 4 | 5 | 6 | 6 | 6 |
| Hold | 5 | 5 | 5 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 23 | 24 | 26 | 26 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $105 | Buy | Maintains | $105 | +76.98% | Jul 23, 2026 |
| Citi | Citi | Buy Maintains $75 → $76 | Buy | Maintains | $75 → $76 | +28.10% | Jul 16, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Reiterates $50 | Hold | Reiterates | $50 | -15.73% | Jul 14, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $66 → $62 | Hold | Maintains | $66 → $62 | +4.50% | Jul 7, 2026 |
| Jefferies | Jefferies | Buy Maintains $104 | Buy | Maintains | $104 | +75.29% | Jul 6, 2026 |
Financial Forecast
Revenue This Year
3.87B
from 3.22B
Increased by 20.23%
Revenue Next Year
4.43B
from 3.87B
Increased by 14.32%
EPS This Year
4.93
from 3.15
Increased by 56.65%
EPS Next Year
6.39
from 4.93
Increased by 29.59%
EPS and Forward PE are based on non-GAAP adjusted numbers.